Evidence map›Paper›PMID 29902993›Full record

ArticleBMC cancer2018

Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes.

Trygve Lofterød, Elin S Mortensen, Hawa Nalwoga, Tom Wilsgaard, Hanne Frydenberg, Terje Risberg, Anne Elise Eggen, Anne McTiernan, Sura Aziz, Erik A Wist and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Metabolic Syndrome and Risks of Breast Cancer Outcomes for Luminal, Triple-Negative, and HER2-Overexpressing Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  14. Review
  15. Article
  16. An analysis of the association between breast density and body mass index with breast cancer molecular subtypes in early breast cancer: data from a Spanish population.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Trygve LofterødDepartment of Oncology, Oslo University Hospital, Ullevål, N-0424, Oslo, Norway. tlofteroed@hotmail.com.
Elin S MortensenDepartment of Clinical Pathology, University Hospital of North Norway, N-9019, Tromsø, Norway.
Hawa NalwogaCentre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, N-5007, Bergen, Norway.
Tom WilsgaardDepartment of Community Medicine, Faculty of Health Services, UIT The Arctic University of Norway, N-9019, Tromsø, Norway.
Hanne FrydenbergDepartment of Oncology, Oslo University Hospital, Ullevål, N-0424, Oslo, Norway.
Terje RisbergDepartment of Oncology, University Hospital of North Norway, N-9019, Tromsø, Norway.
Anne Elise EggenDepartment of Community Medicine, Faculty of Health Services, UIT The Arctic University of Norway, N-9019, Tromsø, Norway.
Anne McTiernanFred Hutchinson Cancer Research Center, Public Health Sciences Division, Seattle, WA, 98109, USA.
Sura AzizCentre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, N-5007, Bergen, Norway.
Erik A WistDepartment of Oncology, Oslo University Hospital, Ullevål, N-0424, Oslo, Norway.
Andreas StensvoldDepartment of Oncology, Østfold Hospital Trust, N-1714 Grålum, Norway.
Jon B ReitanDepartment of Oncology, Oslo University Hospital, Ullevål, N-0424, Oslo, Norway.
Lars A AkslenCentre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, N-5007, Bergen, Norway.
Inger ThuneDepartment of Oncology, Oslo University Hospital, Ullevål, N-0424, Oslo, Norway.
Oslo University Hospital · NOUniversity of Bergen · NOUiT The Arctic University of Norway · NOUniversity Hospital of North Norway · NOFred Hutch Cancer Center · USØstfold Hospital Trust · NO

Funding

EkstraStiftelsen Helse og Rehabilitering 2013/FOM 5628Kreftforeningen 2012/2/0054
6 · The paper itself

Abstract

backgroundHigh triglycerides and low levels of high density lipoprotein (HDL)-cholesterol are observed to promote tumor growth. However, whether breast cancer heterogeneity may explain the contradictory influence of triglycerides and cholesterol observed on breast cancer prognosis remains unclear.

methodsA population-based survival study among 464 breast cancer cases identified within the Tromsø study was conducted. Pre-diagnostic triglycerides, total-cholesterol and HDL-cholesterol were measured, and detailed clinical and histopathological data were obtained. Using tissue microarray, all breast cancer cases were reclassified into the following subtypes: Luminal A, Luminal B, HER2-enriched, and triple negative breast cancer (TNBC). Multivariable Cox proportional hazards regression models were used to study the associations between pre-diagnostic lipids and breast cancer recurrence, mortality, and survival.

resultsA total of 464 breast cancer patients, with mean age at diagnosis of 57.9 years, were followed for a mean 8.4 years. TNBC patients in the highest tertile of triglycerides (≥ 1.23 mmol/l) had 3 times higher overall mortality compared to TNBC patients in the lowest tertile (≤ 0.82 mmol/l) (HR 2.99, 95% CI 1.17-7.63), and the 5-year overall survival was 19% lower for TNBC patients in the highest vs. lowest tertile of triglycerides (65% vs. 84%). TNBC patients in the highest tertile of the HDL-cholesterol/total-cholesterol ratio (≥0.35), compared to those in the lowest tertile (≤0.27), had a 67% reduced overall mortality risk (HR 0.33, 95% CI 0.12-0.89). No associations were observed between lipids and prognostic outcome among breast cancer patients overall, or among patients with luminal A and luminal B subtypes. Among HER2-enriched patients, pre-diagnostic triglyceride level was inversely associated with overall mortality.

conclusionOur study suggests that pre-diagnostic triglycerides and the HDL-cholesterol/total-cholesterol ratio may independently provide unique information regarding prognostic outcome among triple negative breast cancer patients. However, a small sample size underlines the need for additional studies.

Indexed as

AdultAgedBreast NeoplasmsCholesterol, HDLFemaleHumansMiddle AgedNeoplasm Recurrence, LocalPrognosisProportional Hazards ModelsRisk FactorsTriglyceridesCholesterol, HDLTriglyceridesBreast cancerLipidsMolecular subtypeSurvivalTriple negative breast cancer

Identifiers

PMID29902993
PMCPMC6003110
OpenAlexW2807730951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.